Form S-8 - Securities to be offered to employees in employee benefit plans:
SEC Accession No. 0000950170-25-096912
Filing Date
2025-07-18
Accepted
2025-07-18 16:02:01
Documents
18
Effectiveness Date
2025-07-18

Document Format Files

Seq Description Document Type Size
1 S-8 rare-20250718.htm S-8 118324
2 EX-4.4 rare-ex4_4.htm EX-4.4 141082
3 EX-4.8 rare-ex4_8.htm EX-4.8 17205
4 EX-5.1 rare-ex5_1.htm EX-5.1 13682
5 EX-23.1 rare-ex23_1.htm EX-23.1 4444
6 EX-FILING FEES rare_exfilingfees.htm   iXBRL EX-FILING FEES 40008
7 GRAPHIC img163890588_0.jpg GRAPHIC 34892
8 GRAPHIC img163890588_1.jpg GRAPHIC 34892
  Complete submission text file 0000950170-25-096912.txt   566182

Data Files

Seq Description Document Type Size
20 EXTRACTED XBRL INSTANCE DOCUMENT rare_exfilingfees_htm.xml XML 11775
Mailing Address 60 LEVERONI COURT NOVATO CA 94949
Business Address 60 LEVERONI COURT NOVATO CA 94949 415-483-8800
Ultragenyx Pharmaceutical Inc. (Filer) CIK: 0001515673 (see all company filings)

EIN.: 272546083 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-8 | Act: 33 | File No.: 333-288764 | Film No.: 251134457
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)